Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 41.60
0.00 (0.00%)
Mar 24, 2026, 1:30 PM CST
Tanvex BioPharma Revenue
In the year 2025, Tanvex BioPharma had annual revenue of 400.97M TWD with 1,056.27% growth. Tanvex BioPharma had revenue of 178.95M in the quarter ending December 31, 2025, with 6,268.43% growth.
Revenue
400.97M
Revenue Growth
+1,056.27%
P/S Ratio
27.47
Revenue / Employee
2.00M
Employees
200
Market Cap
11.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.97M | 366.29M | 1,056.27% |
| Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
| Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
| Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
| Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.20B |
| Ever Supreme Bio Technology | 1.02B |
| EirGenix | 1.01B |
| PharmaEngine | 911.42M |
| TCM Biotech International | 685.49M |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 611.35M |
| TaiGen Biopharmaceuticals Holdings | 259.47M |